# CASIF catalysts: CASI Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/casif/catalysts

> CASI Pharmaceuticals, Inc. (CASIF) has no upcoming catalysts in this calendar. The latest recorded is the CID-103 trial start, January 3, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CASIF?

CASI Pharmaceuticals, Inc. (CASIF) has no upcoming catalysts in this calendar. The latest recorded is the CID-103 trial start, January 3, 2025. Press release filed with the SEC (EX-99): "- First patient dosed in Phase 1/2 clinical trial in ITP on January 3, 2025." [Calendar and source filings](https://sec-api.dev/companies/casif/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-25-029652, https://www.sec.gov/Archives/edgar/data/1962738/000110465925029652/tm2510656d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2025-03-31. Cite: https://sec-api.dev/companies/casif/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CASI Pharmaceuticals, Inc. |
| Ticker | CASIF (OTC) |
| SEC CIK | 1962738 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/casif |

## Cash runway

Cash $7.3M as of 2025-12-31; quarterly burn $5.2M; about 4.2 months of runway at that rate (XBRL company facts, accession 0001104659-26-061632).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 15, 2024 | [FOLOTYN (folotyn) trial start](https://sec-api.dev/pdufa/folotyn) | CASIF |  | completed | "CASI announced the first patient was dosed with FOLOTYN® in China on February 15, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962738/000110465925029652/tm2510656d1_ex99-1.htm)) |
| January 3, 2025 | [CID-103 trial start](https://sec-api.dev/pdufa/cid-103) | CASIF |  | completed | "- First patient dosed in Phase 1/2 clinical trial in ITP on January 3, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962738/000110465925029652/tm2510656d1_ex99-1.htm)) |

## Drugs

- [CID-103](https://sec-api.dev/pdufa/cid-103): 
- [FOLOTYN (folotyn)](https://sec-api.dev/pdufa/folotyn): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/casif/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CASIF catalysts: CASI Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/casif/catalysts

```bibtex
@misc{secapidev_companies_casif_catalysts_20261116,
  title        = {CASIF catalysts: CASI Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/casif/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_casif_catalysts_20261116","title":"CASIF catalysts: CASI Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/casif/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
